Kirin Beer Kabushiki Kaisha

Nps Pharmaceuticals, Inc.

Other

Kyowa Hakko Kirin Co., Limited

Rika Nagao

Teruyuki Sakai

Atsuya Takami

Yasunari Fujiwara

Kazuo Kubo

Kazumasa Hasegawa

Toshiyuki Isoe

Hideo Ohta

Nobuaki Eto

Teruyuki Saki

Akihiro Ueno

Tomoko Watanabe

Mikio Yagi

Tetsuko Kazama

An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and&#x2003;represents a single bond or a double bond, Rrepresents optionally substituted aryl or the like, Z represents &#x2014;N&#x2550;CHRRor the like, Rand Rrepresent H, optionally substituted alkyl, optionally substituted aryl or the like, Rand Rtogether form &#x2550;O, and Rand Rrepresent H, or Rand Rtogether from a bond, and Rand Rtogether form a bond.

Compound inhibiting in vivo phosphorous transport and medicine containing the same

A novel calcium receptor active compound having the formula is provided:Ar&#x2014;[CRR]&#x2014;X&#x2014;[CRR]&#x2014;[CRR]&#x2014;NR&#x2014;[CRR]&#x2014;Arwherein:

Calcium receptor active compounds

An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and Z represent CH or N; Y represents O or S; R, R, and Rrepresent H, alkoxy or the like; Rrepresents H; R, R, R, and Rrepresent H, halogen, alkoxy or the like; Rand Rrepresent H, alkyl or the like; and Rrepresents optionally substituted azolyl.

Quinoline derivatives and quinazoline derivatives having azolyl group

The present invention relates to novel isoxazole and thiazole compounds having an excellent lysophosphatidic acid (LPA) receptor antagonistic activity represented by general formula [1] or salts thereof:wherein R1 and R2 represents an optionally substituted alkyl group or the like; R3 represents a hydrogen atom or the like; R4 represent a group selected from the group consisting of (I) optionally substituted phenyl, aryl, or heterocycle, (II) substituted or nonsubstituted alkyl, and (III) substituted or nonsubstituted alkenyl, alternatively, R3 and R4 may form a ring structure together with a carbon atom to which they bind; and X represents an oxygen atom or a sulfur atom, provided that, when R3 is a hydrogen atom, R4 represents a group other than methyl, and the use thereof as a medicine.

Isoxazole and thiazole compounds and use thereof as medicine

Calcium receptor-active compounds

Growing community of inventors

Gunma, Japan

Rika Nagao